JFG
SUPN icon

Jefferies Financial Group’s Supernus Pharmaceuticals SUPN Stock Holding History

Jefferies Financial Group’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,304
Closed -$2.25M – 2185
2025
Q4 		$2.25M Sell
45,304
-40,875
-47% -$1.99M 0.01% 760
2025
Q3 		$4.12M Buy
86,179
+32,979
+62% +$1.33M 0.02% 426
2025
Q2 		$1.68M Sell
53,200
-28,113
-35% -$901K 0.01% 572
2025
Q1 		$2.66M Buy
81,313
+56,713
+231% +$2.01M 0.02% 474
2024
Q4 		$890K Buy
+24,600
New +$866K 0.01% 922
2024
Q1 		– Sell
-35,108
Closed -$1.02M – 2014
2023
Q4 		$1.02M Buy
+35,108
New +$931K 0.01% 944
2023
Q3 		– Sell
-53,200
Closed -$1.6M – 1978
2023
Q2 		$1.6M Sell
53,200
-35,500
-40% -$1.24M 0.01% 740
2023
Q1 		$3.21M Buy
+88,700
New +$3.41M 0.03% 507

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jefferies Financial Group's SUPN Position: Q1 2026 in Review

Jefferies Financial Group sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 45,304 shares — an estimated $2.25M sold.

Jefferies Financial Group first reported a position in SUPN in Q1 2023 and held it in 8 quarters. The position peaked at $4.12M in Q3 2025. 328 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Jefferies Financial Group reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 45,304 Supernus Pharmaceuticals shares in Q1 2026, an estimated $2.25M.
  • Jefferies Financial Group first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 8 quarters.
  • Jefferies Financial Group's Supernus Pharmaceuticals position peaked at $4.12M in Q3 2025.
  • 328 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.